期刊
BIOMEDICINE & PHARMACOTHERAPY
卷 141, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.111810
关键词
Glioblastoma; Tumor treating fields; Radiotherapy; Adverse events
资金
- Education Department Foundation of Jilin Province [JJKH20201036KJ]
- Health and Family Planning Commission of Jilin Province Foundations [2016Q034, 2017J11]
- Jilin Provincial Science and Technology Foundations [20180414039GH, 20190201200JC]
TTFields is a treatment technology that induces apoptosis of cancer cells by generating an electric field, and is promising for the treatment of glioblastoma with few side effects.
Glioblastoma (GBM) is a challenging cancer with poor prognosis. The classical standard for treatment is safe resection, followed by concurrent chemoradiotherapy with subsequent adjuvant temozolomide (TMZ). Despite several attempts at different treatments, the 5-year survival rate remains poor. In recent years, with the continuous progress of treatment technology, tumor treating fields (TTFields) were preferable. The device could generate an intermediate frequency alternating electric field and induce apoptosis of some specific types of cancer cells with few toxic and side effects. TTFields induced apoptosis through multiple activations of the pathway. TTFields have been Food and Drug Administration (FDA)-approved for diagnosis and recurrent GBM as additional clinical trial results are revealed. This study reviewed the current status, mechanisms, correlations with immune pathways, the prospects of applying TTFields for GBM, and the adverse events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据